A pow­er­ful spend­ing com­mit­tee in Con­gress wants the FDA to ban the use of clin­i­cal tri­al da­ta from Chi­na in fu­ture ap­pli­ca­tions by drug­mak­ers to...

In its first meet­ing in about nine months, the FDA’s ad­vi­so­ry com­mit­tee of on­col­o­gy ex­perts vot­ed 6-3 Thurs­day that a late-stage tri­al for As­traZeneca’s oral...

A fed­er­al judge has dis­missed part of Eli Lil­ly’s law­suit al­leg­ing Em­pow­er Phar­ma­cy mis­led cus­tomers about its com­pound­ed ver­sions of the obe­si­ty drug tirzepatide.

But...

Bris­tol My­ers Squibb’s can­cer drug Kraza­ti has failed its con­fir­ma­to­ry study in sec­ond-line col­orec­tal can­cer, a com­pa­ny spokesper­son con­firmed to End­points News.

Kraza­ti had...

WASH­ING­TON — Supreme Court jus­tices gave a few hints about how they in­tend to rule in a di­vi­sive case for the phar­ma­ceu­ti­cal in­dus­try.

In its...

About 20,000 peo­ple are tak­ing Eli Lil­ly’s obe­si­ty pill Foun­dayo af­ter its first 20 days on the mar­ket, ac­cord­ing to the com­pa­ny’s CEO David Ricks.

This...